ICICI Prudential Nifty Pharma Index Fund Direct growth
Equity • Index • Direct growth
CAGR
₹1,000 invested for 5 years
Fund Info
Equity
Index
Direct growth
Launched On
15 Dec 2022
1.9 years ago
Lock-in Period
No lock-in
NAV
as of 04 Nov 2024
₹17.44
-0.4304% (0.00)
AUM
₹72 Cr
Expense ratio
0.35%
Benchmark
Nifty Pharma
Fund Plan
Get access to more insightful information
By signing up to Upstox today
Tax info and exit load
Taxes
Units held less than 1Y
20%
Units held more than 1Y
12.5%
Exit Load
If units sold anytime
0%
Distribution
Asset split
Equity99.91%
Cash0.09%
What's in this fund?
Sectors
Holdings
Healthcare
100.00%
Fund House
ICICI Prudential
Inc: 01 Oct 1994 • Total AUM: ₹5,61,361 Cr • Rank #3
ICICI Prudential Mutual Fund, started in 1998, has ICICI Bank as its sponsor. The fund house is headed by Nimesh Shah as the CEO. As of 31 March 2024, it has an AUM of ₹7,61,780 Cr. Its reach is spread across over 350 locations and an investor base of more than 9.2 million investors (as of November 2023).
Fund Managers
Nishit Patel
Experience: 3.84 yrs • Total AUM: 2,47,755 Cr
Priya Sridhar
Experience: 0.74 yrs • Total AUM: 2,08,709 Cr
Risk
Category risk
Very high
As provided by the fund house document, this risk is specific to this fund category (Equity). To know the risk of this fund particularly, check 'Risk vs Category'.
Other top rated funds
UTI Nifty Next 50 Index Fund
Equity • Index • Direct Growth
3Y CAGR
17.93%
Expense ratio
0.37%
Tracking error
Below Average
Fund size
High
ICICI Prudential Nifty Next 50 Index
Equity • Index • Direct Growth
3Y CAGR
17.92%
Expense ratio
0.31%
Tracking error
Below Average
Fund size
High
SBI Nifty Index Fund
Equity • Index • Direct Growth
3Y CAGR
11.45%
Expense ratio
0.2%
Tracking error
Low
Fund size
High
UTI Nifty 50 Index Fund
Equity • Index • Direct Growth
3Y CAGR
11.45%
Expense ratio
0.18%
Tracking error
Low
Fund size
High
ICICI Prudential Nifty 50 Index Fund
Equity • Index • Direct Growth
3Y CAGR
11.43%
Expense ratio
0.17%
Tracking error
Low
Fund size
High
1 / 5
Disclaimer: Top rated funds do not constitute any advice. Research data is powered by Morningstar. Please read the offer documents carefully before investing. Upstox shall not accept any liability arising out of your investments.